Here are 1-2 brief analogies to describe Twist Bioscience:

• TSMC for synthetic DNA: Like TSMC manufactures custom semiconductor chips for a vast array of electronics companies, Twist Bioscience manufactures custom-designed synthetic DNA for various biotech and pharma applications.
• Intel for genetic code: Twist Bioscience provides the fundamental "building blocks" or "code" (synthetic DNA) that power innovations in biology and medicine, much like Intel provides the foundational processors for computers.

• Synthetic Genes: Custom-ordered, high-quality DNA sequences used across various research and industrial applications.
• Oligonucleotides: Short, custom-synthesized DNA or RNA strands crucial for PCR, gene editing, and diagnostic assays.
• DNA Libraries: Large, diverse collections of synthetic DNA variants designed for drug discovery, protein engineering, and directed evolution.
• Target Enrichment Panels: Customized DNA panels used to selectively sequence specific genomic regions for next-generation sequencing applications.
• Biopharma Solutions (including Antibody Discovery): Services leveraging synthetic DNA libraries for rapid identification and optimization of therapeutic antibodies and other biopharmaceuticals.
• mRNA Synthesis: Custom synthesis of messenger RNA for research, vaccine development, and therapeutic applications.
• DNA Data Storage: Research and development into using synthetic DNA as a high-density, long-term solution for digital data storage.

Twist Bioscience (TWST) primarily sells its products and services to other companies and institutions, making it a business-to-business (B2B) supplier in the life sciences industry.

Due to the nature of its business, which involves selling synthetic DNA products and services for research and development purposes, and the fact that no single customer accounted for more than 10% of its revenue in recent fiscal years, Twist Bioscience does not typically disclose the names of its "major customers" for general product sales in its public filings. Its customer base is highly diversified across many organizations.

However, Twist Bioscience has entered into several significant strategic partnerships and collaborations with large public companies where it provides its proprietary technology and services for specific applications. These partners can be considered major customers for those specific initiatives:

• Microsoft (NASDAQ: MSFT): Twist Bioscience has a well-known collaboration with Microsoft for DNA data storage, where Twist provides the synthetic DNA for research and development in this emerging field.
• GSK (NYSE: GSK): Twist Bioscience has collaborated with GSK on drug discovery initiatives, providing DNA libraries and other synthetic biology tools to support GSK's research programs.

Beyond these specific partnerships, Twist Bioscience serves a broad range of customers across various categories:

• Pharmaceutical and Biotechnology Companies: This includes large pharmaceutical companies and smaller biotechnology firms that utilize synthetic DNA for drug discovery, therapeutic development, and vaccine research.
• Academic Institutions and Government Laboratories: Universities, research institutes, and government-funded labs use Twist's products for basic and applied research in fields such as synthetic biology, genomics, and proteomics.
• Agriculture, Industrial, and Diagnostics Companies: Customers in these sectors employ Twist's technology for applications like developing genetically modified crops, producing industrial enzymes, creating biofuels, and designing molecular diagnostic tests.

null

Emily Leproust, PhD, Chief Executive Officer and Co-Founder

Dr. Emily Leproust is a co-founder of Twist Bioscience, established in 2013. Before co-founding Twist Bioscience, she held various leadership positions at Agilent Technologies for over a decade, including Director of Applications and Chemistry R&D—Genomics. During her tenure at Agilent, she was instrumental in developing the successful SureSelect product line and initiating the Oligo Library Synthesis technology. Dr. Leproust has co-founded Petri, an accelerator for startups in engineering and biology, and serves on the Board of Directors of GeneDx. She holds numerous patents and has authored over 30 peer-reviewed papers on applications of synthetic DNA.

Adam Laponis, Chief Financial Officer

Adam Laponis serves as the Chief Financial Officer of Twist Bioscience. Further detailed background information regarding previous companies founded or managed, company sales, or a pattern of managing private equity-backed companies was not readily available in the search results.

Patrick Finn, PhD, President and Chief Operating Officer

Dr. Patrick Finn was promoted to President and Chief Operating Officer of Twist Bioscience in October 2022. He joined the company in 2015 and previously held the role of Chief Commercial Officer. Prior to Twist Bioscience, Dr. Finn served as Vice President of Sales at Enzymatics (later acquired by QIAGEN), where he managed commercial activities for North America and Europe. His career also includes roles of increasing responsibility at Agilent Technologies, where he was Director of Business Development, as well as positions at Beckman Coulter Molecular Diagnostics, Invitrogen, and GE Healthcare/Amersham International. Dr. Finn is currently on the Board of Directors at ONI and previously served on the scientific advisory boards of Lasergen and Enzymatics.

Siyuan Chen, Chief Technology Officer

Siyuan Chen joined Twist Bioscience shortly after its founding. He has been a key leader in product development for both the synthetic biology and next-generation sequencing (NGS) product lines. Chen is recognized for his strategic thinking and proven track record in identifying, developing, and commercializing innovative products within the NGS, synthetic biology, and broader life science sectors.

Dennis Cho, Chief Legal Officer and Corporate Secretary

Dennis Cho serves as the Chief Legal Officer and Corporate Secretary for Twist Bioscience. Further detailed background information was not readily available in the search results.

1. Uncertainty of Achieving Profitability and Managing Cash Burn: Twist Bioscience consistently faces net losses and uncertainty regarding its ability to achieve sustained profitability, despite revenue growth. The company's business model involves significant cash burn due to ongoing investments in research and development and operational expansion. This financial performance, including negative earnings per share and return on equity, highlights a critical challenge in stabilizing its financial position and attracting investor confidence.
2. Intense Competition and Pricing Pressures: The synthetic biology sector is highly competitive, with established companies and new entrants continuously innovating and vying for market share. Competitors, including Chinese firms like BGI and other U.S. peers, are increasing DNA synthesis capacity and often offer lower price points. This intense competition leads to significant pricing pressures that can erode Twist Bioscience's margins and impact its profitability, requiring continuous innovation and differentiation to maintain its market position. There is also a risk that rapidly changing technologies could render Twist's products obsolete or non-competitive.
3. Evolving Regulatory Landscape and Biosecurity Concerns: Twist Bioscience operates within a dynamic regulatory environment, particularly concerning low-cost DNA synthesis and synthetic biology. Governments, including the U.S. with National Security Memorandum 10, are increasing oversight of synthetic biology as a dual-use technology, which could lead to tighter regulations and delays in commercialization. The company is also subject to international regulations, such as the Export Administration Regulations (EAR) and the EU's IVDR, necessitating adherence to complex compliance frameworks. Additionally, there are biosecurity concerns related to the potential misuse of AI-designed sequences of protein variants of toxins and viral proteins, which require the company to invest considerable resources in biosecurity programs and screening protocols.

The emerging threat to Twist Bioscience is the rise of enzymatic DNA synthesis (EDS) technologies, particularly the development and commercialization of benchtop DNA printers by companies like DNA Script. This technology offers an alternative to Twist's proprietary silicon-based chemical DNA synthesis, potentially enabling on-demand, in-lab DNA production that could disrupt the centralized, high-throughput manufacturing model that is fundamental to Twist Bioscience's business.

Twist Bioscience (TWST) operates in several key markets, primarily leveraging its proprietary silicon-based DNA synthesis platform. The addressable market sizes for its main products and services are outlined below:

• Gene Synthesis and Oligo Pools: The global gene synthesis market, which encompasses synthetic DNA and oligo pools, is anticipated to grow from approximately USD 2.04 billion in 2024 to USD 12.88 billion by 2033, at a Compound Annual Growth Rate (CAGR) of 22.74%. The broader global synthetic biology market, where Twist Bioscience is a key player, is projected to reach $38.7 billion by 2028, growing at a CAGR of 17.2% from 2023 to 2028. Another estimate for the synthetic biology market indicates it could become a $56 billion global market by 2028.
• Antibody Discovery Services: The global antibody discovery market was valued at USD 1.6 billion in 2023 and is projected to exceed USD 6.2 billion by 2035, with a CAGR of 12% from 2023 to 2035.
• DNA Data Storage: While Twist Bioscience has historically pursued DNA data storage as a long-term opportunity, it recently spun off this business into an independent company, Atlas Data Storage, in which Twist retains a minority ownership. Twist had previously highlighted an unmet enterprise storage demand projected to exceed $7 billion in the coming years, particularly needing new storage media beyond 2025. This "zone of potential insufficiency" could amount to 7.9 million petabytes (7.9 ZB) by 2030, assuming a 35% annual growth rate in enterprise storage demand, or over 25 ZB with a 45% annual growth rate. Twist also stated that archival data storage is a $35 billion market.
• Next-Generation Sequencing (NGS) Tools: null

1. Continued Growth in Next-Generation Sequencing (NGS) Products, particularly in Liquid Biopsy and Minimal Residual Disease (MRD) Applications: Twist Bioscience anticipates significant growth in its NGS segment, driven by existing customers scaling their product usage and the increasing adoption of applications like liquid biopsy and MRD. The company expects over 20% growth in its NGS business, with this segment offering meaningful growth potential.
2. Expansion of the Synthetic Biology (SynBio) Product Portfolio and Customer Base: The SynBio segment is a core part of Twist Bioscience's business and is expected to continue its growth trajectory. The company aims to achieve this by delivering an exceptional customer experience, expanding its product portfolio, deepening its reach into the academic market, and adding new customers. Initiatives like the Express portfolio have contributed to continued share gains.
3. Advancements and Growth in Biopharma Programs and Partnerships: Although currently a smaller revenue contributor, the biopharma segment is expected to recover and grow, driven by strong synergies with the SynBio division and the initiation of new programs. Twist Bioscience is leveraging its platform for discovery partnerships in biologic drugs.
4. Ongoing Product Innovation and Development, Including New Workflows and Enzymes: Twist Bioscience consistently emphasizes its commitment to innovation, including the introduction of new products and differentiated workflow opportunities. Recent examples include the launch of the Trinity Freestyle™ Sequencing Workflow in collaboration with Element Biosciences and the addition of Twist-developed enzymes to its portfolio, which are seen as new vectors for profitable growth.
5. Leveraging Operational Efficiencies and Cost Leadership to Drive Market Share: While not a direct revenue driver, Twist Bioscience's focus on continuous process improvement, automation, and operational excellence is leading to significant gross margin expansion. This cost leadership, enabled by its proprietary silicon chip technology, allows the company to gain market share and sustain its revenue growth trajectory by offering competitive solutions.

Share Repurchases

• Twist Bioscience repurchased common stock valued at $4.0 million in 2024.
• The company's common stock repurchases amounted to $4.4 million in 2023 and $7.8 million in 2022.
• In 2021, share repurchases totaled $10.8 million.

Share Issuance

• Twist Bioscience issued $269.8 million in common stock during 2022.
• The company also issued $323.9 million in common stock in 2021.
• The number of shares outstanding has shown a consistent increase over the past several years, growing by 2.93% in the last year alone.

Outbound Investments

• Twist Bioscience's "Purchase of investments" totaled $51.9 million in 2024, $76.3 million in 2023, and $217.6 million in 2022.
• Net acquisitions by the company were $13.9 million in 2022.

Capital Expenditures

• Capital expenditures for Twist Bioscience were $5.1 million in 2024, $27.8 million in 2023, and $101.9 million in 2022.
• For the last 12 months, capital expenditures were reported at approximately $17.58 million.
• These expenditures are primarily focused on expanding and enhancing its proprietary silicon-based DNA synthesis platform and manufacturing processes.